Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OMIT Trial: Omitting Therapeutic Lymph Node Dissection in Patients With Stage IIIB/C Melanoma and Major Pathological Response in the Index Lymph Node After Neoadjudvant Immunotherapy

NCT06754904 is registered in ClinicalTrials.gov with D.J. (Dirk) Grünhagen as lead sponsor.

NCT NCT06754904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06754904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OMIT Trial: Omitting Therapeutic Lymph Node Dissection in Patients With Stage IIIB/C Melanoma and Major Pathological Response in the Index Lymph Node After Neoadjudvant Immunotherapy
Lead sponsor
D.J. (Dirk) Grünhagen
Phase
Not applicable
Overall status
Recruiting
Start date
April 23, 2025
Completion date
April 1, 2032
Enrollment
213 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, skin